By Elise Reuter
Published August 27, 2026
The landscape of diabetes management in the United States is standing on the precipice of a tectonic shift. As the Centers for Medicare and Medicaid Services (CMS) deliberates on a proposed expansion of coverage for continuous glucose monitors (CGMs), industry giants Dexcom and Abbott are bracing for a potential influx of millions of new patients. For the 25 million Americans living with Type 2 diabetes who do not rely on insulin, this federal decision could represent the most significant advancement in disease management in decades.
The Core Objective: Expanding Access to Non-Insulin Dependent Patients
Currently, Medicare coverage for CGMs is strictly tiered, largely restricted to individuals with Type 1 diabetes or those with Type 2 diabetes who require insulin therapy or have a documented history of severe, problematic hypoglycemia. This criteria effectively excludes a vast swath of the population who struggle with glycemic control but manage their condition through lifestyle modifications, oral medications, or GLP-1 receptor agonists.
Dexcom CEO Jake Leach has characterized the upcoming CMS ruling as a potential "reshaping" of the entire U.S. diabetes care model. Industry analysts agree, noting that removing the insulin-dependency barrier would validate the clinical utility of CGMs as a preventative tool rather than just a reactive one. By providing real-time data to patients who previously relied on intermittent finger-prick testing—or no testing at all—the healthcare system could see a dramatic pivot toward proactive, data-driven disease management.
Chronology of a Regulatory Pivot
The path to this potential expansion has been paved with years of clinical evidence and persistent lobbying by medical device manufacturers.
- Pre-2026: Medicare coverage for CGMs remained limited to high-risk, insulin-dependent patients, creating a "gap in care" for millions of Type 2 diabetics.
- Summer 2026: Dexcom unveiled definitive results from a 26-week randomized, controlled trial at the American Diabetes Association’s (ADA) Scientific Sessions. The study provided the "gold standard" evidence required to influence federal policy.
- July 2026: During second-quarter earnings calls, executives from both Dexcom and Abbott publicly acknowledged they were in active dialogue regarding the timeline for the expansion.
- Late 2026 (Expected): CMS is anticipated to issue a formal decision regarding the expansion of coverage.
- Mid-2027 (Projected): Should the ruling be favorable, the industry expects the new coverage policies to go into effect, marking the beginning of a new era of accessibility.
Supporting Data: Clinical Evidence for CGM Efficacy
The impetus for this expansion is not merely commercial; it is clinical. The study presented by Dexcom earlier this summer serves as the bedrock of the argument for wider access. The 26-week trial demonstrated that participants using CGMs achieved a statistically significant reduction in hemoglobin A1C levels compared to the control group.
Perhaps more importantly, the study highlighted the "time-in-range" (TIR) metric—the percentage of time a patient spends with blood glucose levels in the target range. CGM users saw a substantial increase of five hours per day in the target range compared to their counterparts. For the Medicare population, which is statistically more prone to diabetes-related complications such as neuropathy, retinopathy, and cardiovascular events, these results suggest that CGM adoption could significantly reduce long-term healthcare expenditures by preventing the onset of acute and chronic complications.
Official Responses and Strategic Positioning
The two dominant players in the space, Dexcom and Abbott, are responding to the potential market expansion with significant operational scaling.
The Dexcom Perspective
Dexcom’s leadership remains optimistic about the timeline. CEO Jake Leach noted in late July that the company expects a decision before the end of the year. With approximately 12.5 million Medicare-age individuals falling into the non-insulin-dependent Type 2 category, the market opportunity is immense. Dexcom is currently positioning its hardware to be more accessible, focusing on ease of use and seamless data integration, which is essential for a demographic that may be less accustomed to high-tech medical devices.
The Abbott Perspective
Abbott, led by CEO Robert Ford, is equally bullish. During the company’s recent earnings call, Ford emphasized that the expansion could make roughly 10 million additional Medicare recipients eligible for their FreeStyle Libre systems. "This could be a multibillion-dollar opportunity, and it could happen in the fall," Ford remarked.
Abbott is currently in a state of high-readiness, retooling its sales force and distribution networks to ensure that supply chain agility keeps pace with the expected surge in demand. By prioritizing commercial insurance alignment alongside the Medicare expansion, Abbott aims to capture a broad market share across both public and private health sectors.
Implications for the Healthcare Ecosystem
The ripple effects of a CMS expansion will extend far beyond the balance sheets of Dexcom and Abbott.
1. The Financial Impact on Medicare
While the upfront cost of providing CGMs to millions of beneficiaries is significant, the long-term economic argument rests on the "value-based care" model. By catching glycemic excursions early, the medical system may avoid the high costs of emergency room visits, hospitalizations for diabetic ketoacidosis, and the treatment of long-term diabetes-related complications.
2. A Shift in Patient Behavior
For patients, the transition from episodic testing to continuous monitoring represents a paradigm shift. The visibility provided by CGM data empowers patients to make immediate, informed decisions regarding their diet and activity. This "feedback loop" has been proven to improve adherence to treatment plans and foster a more proactive relationship between patients and their endocrinologists.
3. Competitive Landscape
The race to capture the non-insulin-dependent market is accelerating. As both companies report strong financial growth—Dexcom with a 13% year-over-year revenue increase ($1.31 billion) and Abbott’s diabetes care segment growing by 10.5% ($2.19 billion)—the competition is fueling innovation. We can expect to see smaller, more discrete sensors, enhanced smartphone integration, and sophisticated AI-driven predictive analytics that alert patients to potential hypoglycemia before it occurs.
4. Broader Insurance Adoption
Medicare often serves as the "north star" for private commercial insurers. When CMS expands coverage, it creates a standard of care that private insurance providers find difficult to ignore. If Medicare deems CGMs medically necessary for non-insulin-dependent Type 2 diabetics, the industry anticipates a rapid domino effect, with major private insurers likely following suit to remain competitive and improve the long-term health outcomes of their covered populations.
Conclusion: A Turning Point for Public Health
The decision currently resting with the CMS is more than a regulatory hurdle; it is a vital milestone in the evolution of chronic disease management. By acknowledging the clinical necessity of continuous monitoring for those with Type 2 diabetes who do not rely on insulin, the federal government is signaling a commitment to data-driven, preventative care.
As the industry awaits the final verdict, both Dexcom and Abbott are signaling that they are not just ready for the change—they are actively building the infrastructure to sustain it. If the decision arrives as expected by the end of 2026, the year 2027 will likely be remembered as the moment the U.S. healthcare system finally brought the power of continuous data to the millions who have long been on the sidelines of the diabetes tech revolution.
For the millions of seniors managing their health, this is not just about technology—it is about the freedom to live with greater confidence, better control, and the potential for a healthier, more active life.
